Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Patienceiskeeon Mar 24, 2022 9:50am
52 Views
Post# 34540963

Sad disappointed but true

Sad disappointed but trueCoronavirus has been throwing new challenges everyday. Recently, the World Health Organisation (WHO) confirmed the possibility of recombinant viruses. Last week, the WHO had confirmed the emergence of a new recombinant virus which is a combination of the BA.1 and BA.2 Omicron strains. On March 19, the WHO tweeted an explainer on a recombinant of Delta AY.4 and Omicron BA.1. "Recombinants are expected as #SARSCoV2 is widespread among humans and many animal species now. Testing, surveillance (including ILI & SARI), sequencing & data sharing are still important to keep track of the pandemic & take early action when new variants emerge," WHO Chief Scientist, Soumya Swaminathan, tweeted on Sunday.
<< Previous
Bullboard Posts
Next >>